Biofarm Bucure - Asset Resilience Ratio
Biofarm Bucure (BIO) has an Asset Resilience Ratio of 8.67% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how Biofarm Bucure's Asset Resilience Ratio has changed over time. See Biofarm Bucure (BIO) financial flexibility to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down Biofarm Bucure's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see BIO stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | RON0.00 | 0% |
| Short-term Investments | RON55.00 Million | 8.67% |
| Total Liquid Assets | RON55.00 Million | 8.67% |
Asset Resilience Insights
- Limited Liquidity: Biofarm Bucure maintains only 8.67% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Biofarm Bucure Industry Peers by Asset Resilience Ratio
Compare Biofarm Bucure's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329 |
Drug Manufacturers - Specialty & Generic | 5.92% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 4.31% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Zhejiang Tianyu Pharmaceutical Co Ltd
SHE:300702 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Zhejiang Anglikang Pharmaceutical Co Ltd Class A
SHE:002940 |
Drug Manufacturers - Specialty & Generic | 9.11% |
Annual Asset Resilience Ratio for Biofarm Bucure (2020–2025)
The table below shows the annual Asset Resilience Ratio data for Biofarm Bucure.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-09-30 | 8.67% | RON55.00 Million ≈ $12.63 Million |
RON634.39 Million ≈ $145.67 Million |
-2.49pp |
| 2024-09-30 | 11.16% | RON62.00 Million ≈ $14.24 Million |
RON555.48 Million ≈ $127.55 Million |
-7.27pp |
| 2023-09-30 | 18.43% | RON91.00 Million ≈ $20.90 Million |
RON493.81 Million ≈ $113.39 Million |
+12.79pp |
| 2020-09-30 | 5.64% | RON21.00 Million ≈ $4.82 Million |
RON372.38 Million ≈ $85.50 Million |
-- |
About Biofarm Bucure
Biofarm S.A. manufactures and sells medicines in Romania. The company offers a portfolio of products covering therapeutic areas, such as antiallergics, cardiovascular and circulatory, analgesics and antipyretics, dermatology, digestive and metabolic, endocrine, genitourinary, multivitamins, ophthalmology, musculoskeletal, respiratory and ENT, and neurology. It provides prescription and non-prescr… Read more